While the world awaits an efficient vaccine for coronavirus, many therapeutics are currently being investigated in hope to improve clinical outcomes. One of the most promising one is currently remdesivir. Wang et al. published the first randomised placebo-controlled trial of its use in severe COVID-19.
Combination of clinical prediction tool and D-dimer should be used in diagnostic algorithm for most cases of suspected pulmonary embolism. Current practice use cut-off of 500 ng/ml for negative in low probability cases. Pulmonary Embolism Graduated D-Dimer (PEGeD) Study looked at the use of D-dimer adjusted to clinical probability in order to decrease the burden of diagnostic imaging in selected patients.